Heloïse Bourien, Leïla Bengrine Lefevre, Marie-Ange Mouret-Reynier, Bernard Asselain, Brigitte Lucas, Celine Gavoille, Corina Cornila, Laurene Gavoille, Emeline Colomba, Anne Patsouris, Michel Fabbro, Camille Chakiba, Philippe Toussaint, Helene Simon, Dominique Berton, Delphine Garbay, Claire Garnier Tixidre, David Coeffic, Aurelie Morvan, Olivier Collard, Thibault DE LA Motte Rouge
BACKGROUND/AIM: Olaparib was approved in 2014 by the European Medicines Agency (EMA) as maintenance treatment for patients with breast cancer gene (BRCA)-mutated platinum-sensitive relapsed high-grade epithelial ovarian cancer (EOC) following the results of the Study 19. We present the results of a national real-world study on the effectiveness of olaparib in relapsed BRCA-mutated EOC patients. PATIENTS AND METHODS: Patients with EOC, peritoneal, and/or fallopian-tube cancer treated with olaparib in a French Center between May 2014 and March 2017 were included...
February 2023: Anticancer Research